Perceived barriers of DCTs can be quickly overcome to ensure their viability in clinical research.
In this interview from DIA 2023, Janice Chang, CEO of TransCelerate BioPharma, discusses the unique opportuntities presented by decentralized clinical trials (DCTs).
Olaparib Demonstrates Efficiency in Biochemically Recurrent Prostate Cancer
August 30th 2024According to a recent Phase II clinical trial conducted by Johns Hopkins Kimmel Cancer Center, all enrolled patients experienced a prostate-specific antigen reduction of 50% or more when treated with Olaparib.